• Startseite
• lx arp1
• CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

4.6 (444) · € 33.99 · Auf Lager

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect

CAR T-cell therapy for patients with multiple myeloma

Physiological lentiviral vectors for the generation of improved CAR-T cells - ScienceDirect

Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. - Abstract - Europe PMC

Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies

Cancer Immunotherapy Therapeutic Strategies in Veterinary Oncology

Frontiers Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Frontiers Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

PDF) CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome